| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Michael J. Detke last filed a Form 4 in March 2022, as Chief Medical Officer at QNCX. Michael J. Detke's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Michael J. Detke's trades have earned a strong insider score of 70/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +96.4%.
At the last filing, the largest reported position was 140,000 shares of QNCX. The QNCX filings lean toward selling, a net 68,261 shares.
Michael J. Detke has 8 Form 4 filings on record from February 2020 to March 2022, all as Chief Medical Officer at Quince Therapeutics (QNCX), 2020–2022.
The 20 reported transactions were 9 open-market sales, 6 option exercises, 4 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $4.1M.
The largest open-market sale was 58,261 shares of QNCX at an average $54.04 on July 7, 2021, about $3.1M. Twelve months later QNCX was down 96%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.